tbuckley/cabot-search huggingface dataset:
P285 The ‘real-life’ copd patient in the age of laba/lamas: an expansion of the daccord study
Authors: C Vogelmeier, H Worth, R Buhl, CP Criée, C Mailaender, N Lossi, P Kardos
Journal: Thorax (2016)

<h3>Introduction</h3> The prospective, non-interventional DACCORD study collects data from a representative cohort of COPD out-patients across Germany who either initiated or changed COPD maintenance medication prior to entry. Initially, DACCORD consisted of two treatment groups (Glycopyrronium-based therapy vs. any other COPD maintenance medication with the exception of Glycopyrronium). Following the approval of LABA/LAMA fixed-dose combinations (FDC) in 2013, DACCORD was extended to follow an additional cohort of patients receiving any LABA/LAMA FDC over a period of 2 years. <h3>Methods</h3> 5223 patients with complete baseline data (3815 LAMA/LABA FDC vs. 1408 standard treatment group) were analysed here. Baseline exacerbations were evaluated 6 months prior to study entry and were annualised for GOLD 2011 categorization; COPD symptoms were evaluated using the COPD Assessment Test (CAT) and the mMRC questionnaire. Prior and concomitant COPD medication were captured and analysed by substance class. <h3>Results</h3> Baseline characteristics are summarised in Table 1. Based on FEV1 assessment, approx. 75% of patients suffered from moderate to severe COPD. Less than a quarter of patients reported a history of exacerbations and only 6.7% experienced ≥2 exacerbations in the 6 months prior to study entry. Taking into account airflow limitation, COPD symptoms and exacerbation history, 41.5% of patients were categorised as GOLD D. Prior to study entry 1271 patients did not receive COPD maintenance treatment and ICS was withdrawn from 1307 patients. 86.9% of patients with an exacerbation history in the LABA/LAMA-FDC treatment group did not receive additional ICS while 58.5% of patients with an exacerbation history in the standard therapy arm received an ICS-based treatment regimen. <h3>Conclusions</h3> The population recruited has a broad range of disease severity, with a baseline CAT and mMRC mean score suggesting a relatively high degree of symptoms. COPD progression and exacerbations will be recorded over the next 2 years and analysed in relation to the received maintenance medication, which will provide valuable real-life data on the use LABA/LAMA FDCs in daily practice in patients with or without an exacerbation history. <h3>Reference</h3> Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://goldcopd.org/
MA07.09 Mass Spectrometry Profiling and Imaging Platform for Novel Precision Drug Resistance Biomarkers Discovery in EML4-ALK Lung Adenocarcinoma
Authors: Patrick Ma, Pamela Cantrell, Callee Walsh, Sijin Wen, Satoshi Komo, Xiaoliang Wu, Haixia Yang, Erin Seeley
Journal: Journal of Thoracic Oncology (2017)
P244 Haemoglobin mediated proliferation and il-6 release in human pulmonary artery endothelial cells: a role for cd163 and implications for pulmonary vascular remodelling
Authors: L Ramakrishnan, A Anwar, JS Wort, GJ Quinlan
Journal: Thorax (2016)

<h3>Introduction</h3> Pulmonary arterial hypertension (PAH) is characterised by vascular remodelling of pulmonary arterioles. Disrupted iron homeostasis as well as subclinical haemolysis are implicated in PAH, although exact mechanisms remain unknown. IL-6, a proinflamatory cytokine and regulator of iron homeostasis is elevated in PAH patients and also been implicated in pulmonary vascular remodelling in murine models. <h3>Objectives</h3> In this study we explored the influences of free haemoglobin (Hb) on proliferative responses and secondary mediator, IL-6 release in human pulmonary artery endothelial cells (hPAECs). <h3>Methods</h3> Cells were challenged with Hb (10 uM) and/or IL-6 (1–10 ng/mL). Transcriptional regulation was analysed by RT-PCR, protein expression by immunocytochemistry, secretion by ELISA and proliferation by BrdU incorporation. <h3>Results</h3> Novel findings demonstrate that Hb and IL-6 individually and in combination increased proliferation of hPAECs (by 32%, 47% and 63% respectively; p &lt; 0.05). CD163, a Hb scavenger receptor, was basally expressed as mRNA and protein (cell surface) on hPAECs and further modulated by Hb or IL-6 exposure. Hb treatment also caused increased transcription (30%; p &lt; 0.05) and release of IL-6 (107%; p &lt; 0.01) from hPAECs. <h3>Conclusion</h3> This is the first report of Hb-mediated proliferation, CD163 expression and IL-6 release in hPAECs with potential implications for autocrine and paracrine signalling in pulmonary vasculature. Hb uptake may be facilitated via CD163. These studies may provide novel insights regarding mechanisms for haemoglobin driven proliferative and second messenger responses of relevance to PAH.
High Dose Defibrotide as Therapy for Pediatric Patients with Veno-Occlusive Disease of the Liver.
Authors: Gregory A. Hale, Renee M. Madden, Kimberly A. Kasow, Joseph Woodard, Wing H. Leung, Raymond C. Barfield, Usman Yusuf, Edwin M. Horwitz, Rupert Handgretinger
Journal: Blood (2006)
P2.02-027 A Randomized Phase II Trial of S-1 plus Cisplatin or Docetaxel plus Cisplatin with Concurrent Thoracic Radiotherapy for Stage III NSCLC: TORG1018
Authors: Kazuhiko Yamada, Tsuneo Shimokawa, Hiroaki Okamoto, Hiroshi Tanaka, Kaoru Kubota, Kazuma Kishi, Haruhiro Saito, Yuichi Takiguchi, Yukio Hosomi, Terufumi Kato, Daijiro Harada, Noriyuki Masuda, Hisashi Kasai, Yoichi Nakamura, Koichi Minato, Takayuki Kaburagi, Katsuhiko Naoki, Koji Hikino, Takeharu Yamanaka, Koshiro Watanabe
Journal: Journal of Thoracic Oncology (2017)
Abstract A31: 14-3-3 binding sites in full-length and splice variant forms of BRAF V600E modulate the response to RAF inhibitors
Authors: Michael J. Vido, Kaitlyn Le, Justin Rock, Edward J. Hartsough, Neda Dadpey, Andrew E. Aplin
Journal: Clinical Cancer Research (2017)

Abstract The serine/threonine kinase BRAF is mutated in 7% of human cancers, the most frequent alteration being a valine to glutamic acid substitution at amino acid 600 (V600E). BRAF V600E melanomas are highly sensitive to RAF inhibitors but the expression of aberrantly spliced BRAF V600E (BRAF V600E ΔEx) isoforms are associated with resistance in 13-30% of progressing patients. Compared to full-length BRAF V600E, BRAF V600E ΔEx exhibit enhanced dimerization and signaling via ERK1/2 during RAF inhibitor therapy; however, much remains unknown regarding their mechanism of action. The 14-3-3 protein binding sites, serine 365 (S365) and serine 729 (S729), play a complex role in regulating the activity and dimerization of RAF isoforms. All reported BRAF V600E ΔEx isoforms lose the N-terminal 14-3-3 binding site (S365) but retain the C-terminal site (S729); therefore, we analyzed the involvement of 14-3-3 binding sites in response to RAF inhibitor therapy. In full-length BRAF V600E, mutation of S365 to alanine promotes elevated MEK-ERK1/2 signaling and growth in the presence of RAF inhibitor. BRAF V600E ΔEx exhibits increased phosphorylation on S729 during RAF inhibitor therapy. Mutation of S729 to alanine renders the BRAF V600E ΔEx isoforms sensitive to RAF inhibitor, measured by reduced ERK1/2 phosphorylation and cell growth in vitro and in vivo. These data highlight the importance of BRAF V600E 14-3-3 binding sites in mediating targeted therapy resistance in mutant BRAF-driven melanoma. Citation Format: Michael J. Vido, Kaitlyn Le, Justin Rock, Edward J. Hartsough, Neda Dadpey, Andrew E. Aplin. 14-3-3 binding sites in full-length and splice variant forms of BRAF V600E modulate the response to RAF inhibitors. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A31.
Incidence of Cytogenetic Abnormalities In Newly Diagnosed Binet Stage A CLL and Relationship with Prognostic Biomarkers and with Stereotyped B Cell Receptors: Updated Results on 344 Patients Included In the Prospective O-CLL1 GISL Study.
Authors: Sonia Fabris, Giovanna Cutrona, Massimo Gentile, Serena Matis, Emanuela Anna Pesce, Francesco Maura, Gabriella Ciceri, Francesco Di Raimondo, Caterina Musolino, Marco Gobbi, Nicola Di Renzo, Francesca Romana Mauro, Renato Cantaffa, Maura Brugiatelli, Francesco Merli, Simonetta Zupo, Caterina Mammi, Luca Baldini, Francesco Angrilli, Gianni Quintana, Ugo Consoli, Giovanni Bertoldero, Emilio Iannitto, Paolo Di Tonno, Antonio Fragasso, Stefano Molica, Pellegrino Musto, Maria Cristina Cox, Gainluca Festini, Vincenzo Callea, Stefano Sacchi, Agostino Cortelezzi, Giorgio Lambertenghi Deliliers, Robin Foà, Massimo Federico, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
Journal: Blood (2010)
Longterm treatment with temozolomide in high-grade gliomas is feasible and leads to longterm survival in a significant subset of patients
Authors: Dagmar Beier, Peter Hau, Tanja Jauch, Dorothee Koch, Tom Hundsberger, S. Schuth, U. Bogdahn
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

5765 

Introduction: Although survival in patients with high-grade gliomas is relatively poor warranting intensified treatment approaches, postoperative radio-chemotherapy is frequently limited by bone marrow toxicity, usually terminating chemotherapy after 6 cycles of chemotherapy. Clinical studies using Temozolomide (Temodar™; TMZ) have produced promising results concerning survival and long-term feasibility, which is in part due to the lacking cumulative toxicity of TMZ. Nevertheless, no systematic data concerning longterm feasibility of TMZ have been acquired yet. Methods: Within a retrospective field analysis, german neuro-oncologists were approached to report on their treatment strategies with TMZ in high-grade gliomas using a standardized questionnaire. Longterm application of TMZ (more than 12 cycles or more than 12 months of any dose) were analyzed and evaluated for feasibility, efficacy and tolerability. Results: Altogether, 128 patients with WHO Grade III or IV gliomas who fulfilled the study criteria were identified by 49 neuro-oncologists. Most of the patients were treated with the standard scheme using 150 to 200 mg/m2, some were treated according to protocol EORTC 26981/22981 or by modified schemes. In first-line treatment (n=64), the median number of applied cycles was 13 (range, 12 to 40) with a mean progression free duration of 56 weeks (range 52 to 160 weeks). Recurrent patients (n=55) received a median number of 14 cycles (range 12 to 44 cycles), with a median duration of 62 weeks (range 52 to 176 weeks). Grade 3 or 4 (NCI-CTC) toxicity concerning the gastrointestinal system (n=7), leukopenia (n=13), thrombocytopenia (n=7) or infection (n=5) was observed only in a small amount of patients. Nevertheless, toxicity data may underestimate the true incidence of toxicity due to the retrospective character of the study. Conclusion: Although this was a retrospective analysis, we could identify a significant number of patients with longterm application of TMZ. Up to 44 cycles were given and times of up to 160 weeks in the first-line and 176 weeks in the recurrent setting without signs of tumor progression could be reached, indicating that patients with active high-grade gliomas may have well controlled disease over significant periods of time.
P2.02-012 Long-Term Survival of Phase II of Full-Dose Oral Vinorelbine Combined with Cisplatin &amp; Radiotherapy in Locally Advanced NSCLC
Authors: Óscar Juan, Sergio Vazquez, Joaquin Casal Rubio, Jose Luis Fírvida, Francisco Aparisi, José Muñóz, José García Sánchez, Regina Gironés, Martin Lazaro Quintela, Vicente Giner, Alfredo Sánchez Hernández
Journal: Journal of Thoracic Oncology (2017)
P2.03a-027 A Phase I Study of the Non-Receptor Tyrsine Kinase Inhibitor (NKI) Bosutinib in Combination with Pemetrexed in Patients with Advanced Solid Tumors
Authors: Nagla Karim, El-Mustapha Bahassi, Ola Gaber, Nooshin Hashemi Sadraei, John Morris
Journal: Journal of Thoracic Oncology (2017)
Niche Induced Myelodysplasia and Secondary Hematopoietic Neoplasia Caused by Deletion of Dicer1 in Osteoprogenitor Cells.
Authors: Marc HGP Raaijmakers, Siddhartha Mukherjee, Shangqin Guo, Tatsuya Kobayashi, Jesse Schoonmaker, Zinmar Aung, Benjamin L. Ebert, Fatima Al-Shahrour, Robert P Hasserjian, Sonia Vallet, Edward Scadden, Charles P Lin, David T. Scadden
Journal: Blood (2009)
P3.03-017 Fluorescent in situ Hybridization Analysis of MET Gene Status in Malignant Mesothelioma
Authors: Antonella Vigani, Sandra Salvi, Serena Varesano, Simona Boccardo, Paola Ferro, Pier Aldo Canessa, Maria Cristiana Franceschini, Paolo Dessanti, Jean Louis Ravetti, Franco Fedeli, Maria Pia Pistillo, Silvio Roncella
Journal: Journal of Thoracic Oncology (2017)
P1.07-026 Activin A is Associated with Poor Prognosis and Promotes Metastatic Growth in Small Cell Lung Cancer
Authors: Anita Rozsas, Elisabeth Lang, Mir Hoda, Thomas Klikovits, Ildiko Kovacs, Szilvia Torok, Balazs Hegedus, Walter Berger, Walter Klepetko, Michael Grusch, Balazs Dome, Viktoria Laszlo
Journal: Journal of Thoracic Oncology (2017)
Adenovirus Infections in Patients Undergoing Umbilical Cord Blood Hematopoietic Stem Cell Transplantation.
Authors: Gabriela Soriano, Vincent T Ho, Karen K Ballen, Philippe Armand, Corey Cutler, John Koreth, Edwin Alyea, Robert J Soiffer, Lindsey Baden, Joseph H Antin, Francisco M Marty
Journal: Blood (2009)
MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis
Authors: Shaohua Lu, Takashi Eguchi, Kay See Tan, Sarina Bains, Kyuichi Kadota, Natasha Rekhtman, Prasad Adusumilli, William Travis
Journal: Journal of Thoracic Oncology (2017)
P2.01-003 Serum VEGF, MMP-7 and CYFRA 21-1 as Predictive Markers of Lung Metastases from Colorectal Cancer
Authors: Franco Lumachi, Paolo Ubiali, Alessandro Del Conte, Federica D'Aurizio, Renato Tozzoli, Stefano Basso
Journal: Journal of Thoracic Oncology (2017)
Cisplatin-based combination chemotherapy consisting of ifomide, epirubicin, and cisplatin (IEP) is effective for patients with relapsed ovarian carcinoma (ROC) resistant or refractory to TC (paclitaxel/carboplatin)
Authors: F. Murakami, N. Ogawa, A. Yamazaki, M. Yamada, T. Ishiya, K. Katase, K. Hasumi, S. Umezawa, Y. Shimizu
Journal: Journal of Clinical Oncology (2008)

16507 Background: To evaluate the efficacy and toxicity of IEP for patients (pts) with relapsed EOC. Methods: Eligible pts had histologically-confirmed serous, endometrioid, or transitional cell carcinoma of the ovary measuring more than 2 cm in diameter, age ≤ 75 yrs, WHO PS ≤ 3, adequate pulmonary, cardiac, hematopoietic, liver and renal functions, and written informed consent. The IEP regimen was as follows: ifomide, 700 mg/m2 infused over 2 hrs, days 1–7; epirubicin, 50 mg/m2 as a bolus, day 5; and cisplatin 15 mg/m2 infused over 2 hrs, days 1–5. The treatment was repeated at 4-week intervals. Results: Forty eligible pts were enrolled in this study. The median age was 51 yrs (range, 41–64). All pts received more than 6 cycles of TC. Thirty- four of 40 pts (85%) had 1 or more previous chemotherapy other than TC. Histologic types were serous (33 pts), endometrioid (5 pts), and transitional (2 pts). After a median of 4 cycles (range, 2–10), we observed objective responses in 28 pts (70%), with 4 (10%) CRs and 24 (60%) PRs, and 12 (30%) NCs. Median overall survival time (MOS) for all 40 pts was 24.3 months (mo) (range, 4 to 78). MOS of pts achieving CR, PR, and NC were ‘not reached”, 23.6 mo, 8.2 mo, respectively (Log-rank, p < 0.001). The most frequent Grade 3–4 hematologic toxicities were; neutropenia 57.8%, anemia 43.3%, and thrombocytopenia 14.4%. Alopecia (Grade 1–2) occurred in 91.3%, but there was no grade 2 or 3 peripheral neuropathy, nephrotoxicity, or cardiotoxicity. Conclusion: IEP regimen has significant anti-tumor activity with acceptable toxicity and appreciable response duration. Several studies have demonstrated that cisplatin is more effective than carboplatin in almost all platinum-sensitive disease except OC (Lokich J: Cancer Invest 19: 756, 2001). In OC, carboplatin was demonstrated equal to cisplatin in anti-tumor response in optimal disease (GOG 158, AGO), but the equivalency was not demonstrated in suboptimal disease. We must reappraise cisplatin is an agent that should be included in the first line for platinum-sensitive OC. No significant financial relationships to disclose.
Closure of duodenal ulcer perforation using a novel endoloop device with a single-channel gastroscope after failed laparoscopic repair
Authors: Shu Huang, Sumin Zhu
Journal: Endoscopy (2017)

Patients with duodenal ulcer perforation regularly undergo conversion to open surgical repair after the failure of laparoscopic closure [1]. We report the use of a novel endoloop device with a single-channel gastroscope for the closure of a duodenal ulcer perforation after failed laparoscopic repair.
RETRACTED: OA02.03 Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study
Authors: Yawen Dong, Hao Zhang, Karin Schelch, Thomas Klikovits, Paul Stockhammer, Marko Jakopovic, Miroslav Samarzija, Luka Brcic, Glen Reid, Michaela Kirschner, Steven Kao, Isabelle Opitz, Walter Weder, Thomas Frauenfelder, Thi Dan Linh Nguyen-Kim, Walter Klepetko, Nico Van Zandwijk, Balazs Hegedus, Walter Berger, Balazs Dome, Viktoria Laszlo, Michael Grusch, Mir Hoda
Journal: Journal of Thoracic Oncology (2017)
S136 Potential therapeutic benefits of the human amniotic epithelium cell secretome during ex-vivo perfusion of donor lungs
Authors: JW Mayes, K Jiwa, B Leaw, J Tan, S Lau, L Borthwick, A Andreasson, J Dark, G Jenkin, R Lim, AJ Fisher
Journal: Thorax (2016)

<h3>Introduction</h3> Ex-vivo lung perfusion (EVLP) is used to assess and potentially recondition donor lungs that are not initially suitable for transplantation. In a recent UK study, EVLP was associated with higher primary graft dysfunction (PGD) rates compared to standard lung evaluation procedure. PGD is a process characterised by leucocyte-endothelial adhesion and acute lung injury. In this study, donor lung leucocyte content and endothelial activation before and after EVLP was assessed and then the potential of the human amnion epithelial cell (hAEC) secretome to reduce endothelial cell – leucocyte interaction was evaluated. <h3>Methods</h3> Donor lung tissue, pre and post EVLP (n = 16), was stained with CD45, neutrophil elastase and IL-1 receptor type I antibodies to assess endothelial activation, and leukocyte recruitment. Human umbilical vein endothelial cells (HUVECs) and human amnion epithelial cells were isolated from term (n = 5) and preterm (n = 5) placentas. HUVECs activated with IL-1β were used for leucocyte rolling and adhesion studies in an in-vitro model. The effects of hAEC-conditioned media (hAEC secretome) on leucocyte rolling, adhesion and HUVEC expression of adhesion molecules (E-selectin, ICAM-1, and VCAM) was assessed. <h3>Results</h3> CD45 positive cells in the donor lung vasculature significantly decreased during EVLP (<i>p</i> = 0.028). Neutrophil elastase positive cells were significantly lower in <i>accepted</i> donor lungs (n = 4) compared to <i>declined</i> lungs (n = 4) (<i>p</i> = 0.0044). However, IL-1 Receptor Type 1 expression significantly increased after EVLP (<i>p</i> = 0.048). The hAEC secretome derived from both term and pre-term placentas significantly reduced endothelial ICAM-1 levels, <i>p</i> = 0.013 and <i>p</i> = 0.0085 respectively. This was accompanied by a significant decrease in leucocyte rolling and leucocyte-endothelial adhesion, with both term (<i>p</i> = 0.041) and preterm (<i>p</i> = 0.014) hAEC secretome. <h3>Discussion</h3> EVLP reduces the intravascular leucocyte content of the donor lung, probably due to the presence of a leucocyte filter in the perfusion circuit. However, the endothelium remains primed to activation with IL-1 receptor expression increasing during EVLP. The secreted products of hAECs reduce endothelial activation and limit leukocyte-endothelial interactions. Further studies are required in a suitable in-vivo model to determine if hAECs, or their secretome, are a potential therapeutic option during EVLP to protect against primary graft dysfunction after reperfusion of the transplanted lung.
P3.03-049 Optimization of Malignant Mesothelioma Registration at the Belgian Cancer Registry
Authors: Michael Rosskamp, Harlinde De Schutter, Mia Slabbaert, Kris Henau, Marleen Praet, Jan Van Meerbeeck, Kristiaan Nackaerts, Liesbet Van Eycken
Journal: Journal of Thoracic Oncology (2017)
Anti-PD1 therapy effects on T cell repertoire and functions in patients with NSCLC cancer: a preliminary study to identify biomarkers of efficacy
Authors: G. Barra, G. Pasquale, C.M. Della Corte, F. Papaccio, M. Orditura, F. DeVita, F. Ciardiello, R. De Palma, F. Morgillo
Journal: Annals of Oncology (2016)
A molecular portrait of circulating free DNA of patients with breast cancer: High-resolution analysis using SNP 6.0 arrays.
Authors: J. A. Shaw, K. Page, K. Blighe, N. Hava, D. Guttery, B. Ward, J. Brown, C. Ruangpratheep, R. Payne, C. Palmieri, S. Cleator, R. Walker, C. Coombes
Journal: Journal of Clinical Oncology (2011)

555 Background: Early detection and monitoring the progress of common cancers is a continuing problem. Patients with cancer are known to have cancer-derived DNA circulating free in plasma (cfDNA) and we hypothesised that this may form the basis for a means of detecting and monitoring the disease Methods: For the first time, we have characterised cfDNA of breast cancer patients to create a molecular portrait, using high resolution analysis with Affymetrix SNP 6.0 Arrays. This array features 906,600 probes for single nucleotide polymorphisms (SNPs) and 946,000 probes for copy number variation (CNV) detection and represents more genetic variation on a single array than any other array platform. SNP 6.0 profiles of the primary tumour were compared with paired cfDNA samples of 50 breast cancer patients on follow-up after surgical removal of their primary tumour and related to cfDNA results of 15 primary breast cancer patients for whom we collected pre-surgical blood samples and healthy female controls. Results: Concordance of SNP genotype calls distinguished between breast cancer patients and healthy controls (p < 0.0001) and between pre-operative patients and patients on follow-up who had surgery and treatment (p = 0.002). Principal component analysis of plasma SNP/copy number results also separated 15 pre-surgical breast cancer patients from the healthy controls suggesting CNVs in plasma DNA have clinical significance. In the 50 patients on follow-up specific CNVs were detected in plasma, mirroring the primary tumour, up to 10 years after diagnosis despite no other evidence of disease on routine scanning. Finally, we identified focal high level DNA amplification, clustered at 7 chromosome arms, amenable to high throughput approaches for screening and monitoring. Conclusions: This study clearly demonstrates the potential of SNP/CNV analysis of cfDNA to reliably distinguish between patients with primary breast cancer and healthy controls, and for monitoring patients after the completion of surgery, radiation therapy and chemotherapy. Our findings may also apply to other cancers where early detection is essential for cure and dormancy is a feature.
P3.02c-015 Phase II Trial of S-1/Cisplatin Combined with Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: TCOG LC-1202
Authors: Yusuke Okuma, Yukio Hosomi, Akihiko Miyanaga, Koichi Minato, Sakae Fujimoto, Hiromi Aono, Yoshihiro Hattori, Hiroshi Isobe, Hiroaki Okamoto, Yuichi Takiguchi, Kaoru Kubota
Journal: Journal of Thoracic Oncology (2017)